MCID: VLV032
MIFTS: 51

Vulva Cancer

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Vulva Cancer

MalaCards integrated aliases for Vulva Cancer:

Name: Vulva Cancer 12 15
Carcinoma of Vulva 12 60 74
Vulvar Carcinoma 12 60 17
Vulva Carcinoma 12 56 15
Vulvar Cancer 54 38 44
Malignant Neoplasm of Vulva 12 74
Vulvar Neoplasms 45 74
Malignant Tumor of Vulva 12
Malignant Vulvar Tumor 12
Neoplasm of Vulva 12
Vulval Neoplasm 12
Vulvar Neoplasm 12
Vulval Cancer 12
Vulvar Tumor 12
Ca Vulva 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1245 DOID:1294
KEGG 38 H00029
ICD9CM 36 184.4
MeSH 45 D014846
SNOMED-CT 69 94143002
ICD10 34 C51 C51.9
Orphanet 60 ORPHA494418

Summaries for Vulva Cancer

MedlinePlus : 44 Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually grows slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early. Often, vulvar cancer doesn't cause symptoms at first. However, see your doctor for testing if you notice A lump in the vulva Vulvar itching or tenderness Bleeding that is not your period Changes in the vulvar skin, such as color changes or growths that look like a wart or ulcer You are at greater risk if you've had a human papillomavirus (HPV) infection or have a history of genital warts. Your health care provider diagnoses vulvar cancer with a physical exam and a biopsy. Treatment varies, depending on your overall health and how advanced the cancer is. It might include surgery, radiation therapy, chemotherapy, or biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Vulva Cancer, also known as carcinoma of vulva, is related to vulva adenocarcinoma and verrucous carcinoma, and has symptoms including pelvic pain and pruritus vulvae. An important gene associated with Vulva Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are L1CAM interactions and Glioblastoma Multiforme. The drugs Gardasil and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and skin, and related phenotypes are pigmentation and respiratory system

Disease Ontology : 12 A vulva cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

NIH Rare Diseases : 54 Vulvar cancer is the abnormal growth of cells of the vulva, which is part of the female reproductive system and includes the vaginal lips, clitoris, and part of the vagina.  Symptoms of vulvar cancer may consist of a lump (mass), itching, or unusual bleeding.  Though the exact cause of this cancer is unknown, older women and those who have human papillomavirus have a higher chance of developing vulvar cancer.  Treatment may include laser therapy, surgery, chemotherapy, or radiation therapy.

Wikipedia : 77 Vulvar cancer is a malignant, invasive growth in the vulva, or the outer portion of the female genitals.... more...

Related Diseases for Vulva Cancer

Diseases related to Vulva Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 211)
# Related Disease Score Top Affiliating Genes
1 vulva adenocarcinoma 31.5 CDKN2A KRT7 LINC01191 UPK3A
2 verrucous carcinoma 30.4 CDKN2A TP53
3 vulvar intraepithelial neoplasia 30.3 KRT7 TP53
4 anogenital venereal wart 30.2 CDKN2A TP53
5 suppressor of tumorigenicity 3 30.2 CDKN2A TP53
6 vulvar dystrophy 30.1 CDKN2A LINC01191
7 in situ carcinoma 30.1 CDKN2A EGFR TP53
8 papilloma 30.0 CDKN2A KRT13 KRT7 TP53
9 vulvar disease 29.8 CDKN2A KRT13 KRT7 LINC01191 PLXDC2 SCN10A
10 small cell carcinoma 29.8 CDKN2A EGFR KRT7 TP53
11 squamous cell carcinoma 29.8 CDKN2A EGFR SERPINB3 TP53
12 endometrial cancer 29.4 CDKN2A EGFR KRT7 TP53
13 vulva squamous cell carcinoma 29.0 CDKN2A PLXDC2 SERPINB3 SH3GL2 TP53
14 vulva verrucous carcinoma 11.5
15 vulvar basal cell carcinoma 11.2
16 vaginal disease 11.1
17 bartholin's gland carcinoma 11.1
18 vulva basal cell carcinoma 11.1
19 vulvar sebaceous carcinoma 11.1
20 vulvar eccrine porocarcinoma 11.1
21 vulvar clear cell hidradenocarcinoma 11.1
22 vulvar glandular tumor 11.1
23 vulvar melanoma 11.1
24 vulvar sarcoma 11.1
25 clitoris cancer 11.1
26 brain ependymoma 10.4 EGFR TP53
27 malignant peritoneal mesothelioma 10.4 CDKN2A EGFR
28 peritoneal mesothelioma 10.4 CDKN2A EGFR
29 anaplastic oligodendroglioma 10.4 CDKN2A EGFR
30 recurrent respiratory papillomatosis 10.4 EGFR TP53
31 bladder squamous cell carcinoma 10.4 CDKN2A TP53
32 keratinizing squamous cell carcinoma 10.4 CDKN2A TP53
33 benign breast adenomyoepithelioma 10.4 EGFR KRT7
34 spitz nevus 10.4 CDKN2A TP53
35 inverted transitional papilloma 10.4 CDKN2A KRT7
36 breast squamous cell carcinoma 10.4 EGFR TP53
37 oncocytic breast carcinoma 10.4 EGFR KRT7
38 scrotal carcinoma 10.4 CDKN2A TP53
39 thyroid lymphoma 10.4 CDKN2A TP53
40 bartholin's gland disease 10.4 CDKN2A TP53
41 malignant spiradenoma 10.4 KRT7 TP53
42 anal squamous cell carcinoma 10.4 CDKN2A TP53
43 spiradenoma 10.4 KRT7 TP53
44 microglandular adenosis 10.4 EGFR TP53
45 megaesophagus 10.4 CDKN2A TP53
46 gastric adenosquamous carcinoma 10.4 CDKN2A TP53
47 adenoid basal cell carcinoma 10.4 CDKN2A KRT7
48 bile duct adenoma 10.4 CDKN2A KRT7
49 endocervical carcinoma 10.3 CDKN2A KRT7
50 cervix uteri carcinoma in situ 10.3 CDKN2A TP53

Comorbidity relations with Vulva Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Clitoris Cancer
Hypertension, Essential Localized Scleroderma
Vaginal Cancer Vulvar Dystrophy

Graphical network of the top 20 diseases related to Vulva Cancer:



Diseases related to Vulva Cancer

Symptoms & Phenotypes for Vulva Cancer

UMLS symptoms related to Vulva Cancer:


pelvic pain, pruritus vulvae

MGI Mouse Phenotypes related to Vulva Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.26 CDKN2A EGFR LMO7 TP53
2 respiratory system MP:0005388 9.1 CDKN2A EGFR LMO7 SCN10A SH3GL2 TP53

Drugs & Therapeutics for Vulva Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Gardasil 19 50 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck June 2006

Drugs for Vulva Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Octreotide Approved, Investigational Phase 3 83150-76-9 6400441 383414
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
4
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
5 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
6 Liver Extracts Phase 3,Phase 2,Phase 1
7 Cola Phase 3,Phase 2,Phase 1
8 Fibrin Tissue Adhesive Phase 3
9 Coagulants Phase 3
10 Hemostatics Phase 3
11 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
12 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
13 Gastrointestinal Agents Phase 3,Phase 1
14 Antineoplastic Agents, Hormonal Phase 3
15 Narcotics Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Analgesics Phase 3,Phase 2,Phase 1
18 Anesthetics, Intravenous Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics Phase 3
21 Analgesics, Opioid Phase 3
22 Central Nervous System Depressants Phase 3
23 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
24 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
25 DHEA (Dehydroepiandrosterone) Phase 3
26
Indinavir Approved Phase 2 150378-17-9 5362440
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Parathyroid hormone Approved, Investigational Phase 2,Phase 1 9002-64-6
29
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
30
Bevacizumab Approved, Investigational Phase 2 216974-75-3
31
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
32
Pimecrolimus Approved, Investigational Phase 2 137071-32-0 17753757 6447131
33
Clobetasol Approved, Experimental, Investigational Phase 2 25122-46-7, 25122-41-2 5311051 32798
34
Fondaparinux Approved, Investigational Phase 2 104993-28-4
35
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
36
Imiquimod Approved, Investigational Phase 2,Not Applicable 99011-02-6 57469
37
Ipilimumab Approved Phase 2,Phase 1 477202-00-9
38
nivolumab Approved Phase 2,Phase 1 946414-94-4
39 Daratumumab Approved Phase 1, Phase 2 945721-28-8
40
Fludarabine Approved Phase 1, Phase 2,Phase 2 75607-67-9, 21679-14-1 30751
41
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
42
Aldesleukin Approved Phase 1, Phase 2 110942-02-4, 85898-30-2
43
Durvalumab Approved, Investigational Phase 2,Phase 1 1428935-60-7
44
Bupropion Approved Phase 2 34841-39-9, 34911-55-2 444
45
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
46
Pembrolizumab Approved Phase 2 1374853-91-4
47
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
48
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
49
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
50 Cytochrome P-450 Enzyme Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 135)
# Name Status NCT ID Phase Drugs
1 Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva Completed NCT00003325 Phase 3
2 Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes Completed NCT00898352 Phase 3
3 Fibrin Sealant in Decreasing Lymphedema Following Surgery to Remove Lymph Nodes in Patients With Cancer of the Vulva Completed NCT00028951 Phase 3 fibrin sealant
4 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage Completed NCT00224744 Phase 3
5 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
6 Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence Completed NCT01148290 Phase 3
7 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
8 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
9 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) Completed NCT03158220 Phase 3
10 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
11 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
12 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3 octreotide acetate
13 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
14 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
16 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Completed NCT01376349 Phase 3 prasterone
17 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Recruiting NCT02997553 Phase 3 Indocyanine green;Technetium99
18 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) Active, not recruiting NCT00943722 Phase 3
19 Radiation Therapy With or Without Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Cancer of the Vulva Terminated NCT00006096 Phase 3 cisplatin
20 Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer Terminated NCT00577317 Phase 3
21 Bioimpedance Spectroscopy in Detecting Lower-Extremity Lymphedema in Patients With Stage I, Stage II, Stage III, or Stage IV Vulvar Cancer Undergoing Surgery and Lymphadenectomy Unknown status NCT01406769 Phase 2
22 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
23 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
24 Paclitaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Vulva Completed NCT00014599 Phase 2 paclitaxel
25 Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva Completed NCT00068406 Phase 2 Cisplatin
26 The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence Completed NCT01986725 Phase 2
27 Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar Completed NCT00476476 Phase 2 Erlotinib
28 Effectiveness of an Individualized Symptom Education Program (ISEP) Completed NCT00275353 Phase 2
29 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers Completed NCT00545792 Phase 2 Avastin
30 Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus Completed NCT00393263 Phase 2 pimecrolimus and clobetasol;clobetasol 0.05% cream
31 A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) Completed NCT00551187 Phase 2
32 Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
33 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
34 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
35 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
36 Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Recruiting NCT01595061 Phase 2 Cisplatin;Gemcitabine Hydrochloride
37 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
38 Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers Recruiting NCT03403465 Phase 2
39 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;Relatlimab;Daratumumab
40 Image-Guided Gynecologic Brachytherapy Recruiting NCT02993900 Phase 2
41 E7 TCR T Cells for Human Papillomavirus-Associated Cancers Recruiting NCT02858310 Phase 1, Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
42 DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers Recruiting NCT03439085 Phase 2
43 Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Recruiting NCT03180294 Phase 2 Bupropion Hydrochloride
44 Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting NCT02628067 Phase 2
45 Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3) Recruiting NCT03180684 Phase 2 Imiquimod 5% cream
46 Image-Guided Gynecologic Brachytherapy Active, not recruiting NCT01399658 Phase 2
47 Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva Terminated NCT00003525 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
48 Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer Terminated NCT00106262 Phase 2 Velcade (bortezomib);Irinotecan
49 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Withdrawn NCT03220009 Phase 2
50 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1

Search NIH Clinical Center for Vulva Cancer

Cochrane evidence based reviews: vulvar neoplasms

Genetic Tests for Vulva Cancer

Anatomical Context for Vulva Cancer

MalaCards organs/tissues related to Vulva Cancer:

42
Lymph Node, Testes, Skin, Cervix, Brain, Tongue, T Cells

Publications for Vulva Cancer

Articles related to Vulva Cancer:

(show all 38)
# Title Authors Year
1
Impact of re-excision of residual adjacent vulvar intraepithelial neoplasia (VIN III) and histological tumour-free margin (hTFM) on survival in primary squamous cell carcinoma of vulva. ( 30187190 )
2018
2
Assessing Patient-reported Quality of Life Outcomes in Vulva Cancer Patients: A Systematic Literature Review. ( 29420364 )
2018
3
Adenoid Cystic Carcinoma of Vulva-11 Years' Single-Institution Experience. ( 28546667 )
2017
4
Locally advanced vulva cancer: A single centre review of anovulvectomy and a systematic review of surgical, chemotherapy and radiotherapy alternatives. Is an international collaborative RCT destined for the "too difficult to do" box? ( 28034465 )
2017
5
Vulva cancer in Ghana - Review of a hospital based data. ( 28409179 )
2017
6
Surgical management for squamous cell carcinoma of vulva. ( 27642483 )
2016
7
Could sentinel node mapping of the groin cause extranodal metastasis in vulva cancer? ( 25412581 )
2015
8
An unusual case of mammary gland-like carcinoma of vulva: case report and review of literature. ( 26189264 )
2015
9
Oncogenic viruses associated with vulva cancer in HIV-1 patients in Botswana. ( 25225572 )
2014
10
Preliminary study on human papillomavirus frequency and specific type-distribution in vulva cancer from Thai women. ( 23725140 )
2013
11
Tumor-to-tumor metastasis with endometrial carcinoma metastatic to squamous cell carcinoma of vulva: the first reported case. ( 24283863 )
2013
12
Verrucous squamous cell carcinoma of vulva simulating multiple epidermal inclusion cysts. ( 23919011 )
2013
13
The comparative study of former and latest FIGO staging of vulva cancer. ( 22487921 )
2012
14
Small cell carcinoma of vulva: curative multimodal treatment in face of resistance to initial standard chemotherapy. ( 20803181 )
2010
15
Treatment outcome of patients with carcinoma of vulva: experience from a tertiary cancer center of India. ( 21358089 )
2010
16
Assessment of promising protein markers for vulva cancer. ( 19509584 )
2009
17
Cyberknife radiosurgery for squamous cell carcinoma of vulva after prior pelvic radiation therapy. ( 18783287 )
2008
18
Verrucous carcinoma of vulva. ( 17917632 )
2007
19
An alternative approach to ganglion impar neurolysis under computed tomography guidance for recurrent vulva cancer. ( 17006101 )
2006
20
Images in pathology. Invasive squamous cell carcinoma of vulva that wanted to be a puppy. ( 17041202 )
2006
21
Clinico-pathological profile of vulva cancer in southern Thailand: analysis of 66 cases. ( 16149671 )
2005
22
Invasive squamous cell carcinoma of vulva: prognostic significance of clinicopathologic parameters. ( 15861524 )
2005
23
Correspondence re: Weiderpass et al., Alcoholism and risk of cancer of cervix uteri, vagina, and vulva. Cancer Epidemiol. Biomark. Prev., 10: 899-901, 2001. ( 11895888 )
2002
24
Response to "Inguinal node status by ultrasound in vulva cancer" (Abang Mohammed et al. Gynecol Oncol 2000;77:93-6). ( 11277664 )
2001
25
Treatment of verrucous carcinoma of vulva with acitretin. ( 10848746 )
2000
26
Inguinal node status by ultrasound in vulva cancer. ( 10739696 )
2000
27
Cervical and vulva cancer: changes in FIGO definitions of staging. ( 8624311 )
1996
28
T2/3 vulva cancer: a case-control study of triple incision versus en bloc radical vulvectomy and inguinal lymphadenectomy. ( 7774837 )
1995
29
Concurrent squamous cell carcinoma of vulva and penis in a married couple. ( 3373472 )
1988
30
Therapy of advanced epidermoid carcinoma of vulva. Report of 13 patients, with review of recent literature. ( 1165879 )
1975
31
Cutaneous basal cell carcinoma of vulva. ( 1192371 )
1975
32
Carcinoma of vulva in Singapore: a review of 12 cases. ( 5084234 )
1972
33
Effects of long-term administration of busulfan. Report of a patient with generalized nuclear abnormalities, carcinoma of vulva, and pulmonary fibrosis. ( 5255526 )
1969
34
SURGICAL TREATMENT OF CARCINOMA OF VULVA. ( 14214238 )
1964
35
Intraepithelial and infiltrative carcinoma of vulva: Bowen's type. ( 13680991 )
1961
36
Infiltrative squamous cell (epidermoid) carcinoma of vulva. ( 13707356 )
1961
37
Carcinoma of vulva following granuloma inguinale. ( 12996727 )
1952
38
A case of carcinoma of vulva secondary to a primary growth in the breast. ( 20996160 )
1946

Variations for Vulva Cancer

Cosmic variations for Vulva Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM12296 TP53 skin,lip,carcinoma,NS c.292C>T p.P98S 17:7676077-7676077 0
2 COSM10662 TP53 skin,lip,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 0
3 COSM26363 PTCH1 skin,lip,carcinoma,NS c.2446C>T p.Q816* 9:95467230-95467230 0
4 COSM17598 PTCH1 skin,lip,carcinoma,NS c.550C>T p.Q184* 9:95485719-95485719 0
5 COSM498 HRAS skin,genital,carcinoma,NS c.182A>T p.Q61L 11:533874-533874 0

Expression for Vulva Cancer

Search GEO for disease gene expression data for Vulva Cancer.

Pathways for Vulva Cancer

GO Terms for Vulva Cancer

Biological processes related to Vulva Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.16 EGFR SH3GL2
2 replicative senescence GO:0090399 8.96 CDKN2A TP53
3 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 8.62 EGFR TP53

Molecular functions related to Vulva Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 8.92 CDKN2A EGFR SH3GL2 TP53

Sources for Vulva Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....